A fingerprint construction method of a traditional Chinese medicine composition containing rehmannia root, cornus officinalis and wolfberry and its application
Through high-performance liquid chromatography detection, fingerprint maps of the traditional Chinese medicine compound prescriptions of Rehmannia, Cornus de Trichoderma and Wolfberry were established, solving the problem that the quality of the traditional Chinese medicine compound prescriptions cannot be comprehensively analyzed and controlled in the existing technology, and achieving the overall quality control and efficacy guarantee of the traditional Chinese medicine compound prescriptions.
Patent Information
- Application Number
- CN202410444113.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-04-12
AI Technical Summary
The existing technology fails to comprehensively analyze and control the chemical components of traditional Chinese medicine compound containing Rehmannia, Cornus and wolfberry, and cannot effectively ensure its production process and product quality, which affects clinical efficacy.
The octadecyl bonded silica gel chromatography column was used, acetonitrile, methanol and tetrahydrofuran were used as mobile phases, gradient elution procedures and acid water and alkali aqueous solutions were used for high-performance liquid chromatography detection, and the fingerprint map of the traditional Chinese medicine composition was established, and 15 common characteristics were determined. Peaks to ensure the stability and quality control of chemical composition.
The overall quality control of the benchmark samples of Chinese medicine compound is achieved, ensuring the efficacy and safety of the drug, providing an important reference for the quality control of Chinese medicine compound, and solving the problems of difficulty in separation of fingerprint characteristic peaks and interference with impurity peaks.
Smart Images

Figure CN118425346B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a method for constructing a fingerprint of a traditional Chinese medicine composition comprising rehmannia root, cornus officinalis and wolfberry, and an application thereof. Background Art
[0002] According to the Traditional Chinese Medicine Law of the People's Republic of China, ancient classic prescriptions refer to "prescriptions recorded in ancient Chinese medicine classics that are still widely used, have definite efficacy, and have obvious characteristics and advantages". Ancient classic prescriptions have a long and rich history of human use in my country and are still used today. They are the summary of the essence of clinical practice of doctors of all dynasties, carrying the profound accumulation of the splendid civilization of traditional Chinese medicine for thousands of years. They are the result of thousands of years of tempering of traditional Chinese medicine theory, the summary of clinical experience of all dynasties, and the most essential part of the great treasure house of traditional Chinese medicine.
[0003] As the most commonly used dosage form of traditional Chinese medicine clinical medicine, decoctions of classic Chinese medicine prescriptions have the advantages of reasonable formulation, rapid onset, significant efficacy, and easy absorption, and are deeply trusted by the majority of patients. However, due to the shortcomings of easy mold and deterioration during preparation, carrying, temporary decoction, and long-term storage, the bitter taste and large amount of decoction, and the difficulty in standardization, which seriously affects its clinical efficacy, it cannot adapt to the living requirements of modern people. In order to maintain the advantages of decoctions and overcome the various shortcomings of decoctions, the "Technical Guiding Principles for Pharmaceutical Research of Traditional Chinese Medicine Compound Preparations Managed by the Catalog of Ancient Classic Prescriptions (Trial)" issued by the Drug Evaluation Center of the State Food and Drug Administration on August 31, 2021 clearly pointed out that the quality of traditional Chinese medicine compound preparations managed by the catalog of ancient classic prescriptions should be basically consistent with the quality of the classic prescription benchmark samples. The benchmark sample represents the overall intrinsic quality of the preparation. Except for the molding process, the benchmark sample and the other quality control indicators of the preparation are basically consistent. Therefore, the benchmark sample is a physical comparison of the intrinsic quality of the preparation and a reference for the optimization of large-scale production processes and the formulation of its quality standards. Benchmark samples are the benchmark for classic prescriptions and even all Chinese medicine research and development, and are the reference materials to ensure the safety and effectiveness of drugs. The production process route formulation, parameter optimization and quality standard formulation of classic prescription compound preparations should be based on the benchmark samples of classic prescriptions. Benchmark samples are the link between clinic, enterprise and scientific research, and are the benchmark for inheriting, applying and promoting traditional Chinese medicine.
[0004] Fingerprint is based on the understanding of the overall effect of Chinese medicine substance groups. It uses spectral and chromatographic techniques to obtain the spectrum or chromatogram of Chinese medicine chemical components. It is a feasible model for identifying the authenticity of Chinese medicine, evaluating quality consistency and product stability. It has the characteristics of large amount of information, strong characteristics, integrity and fuzziness. Chinese medicine fingerprint can comprehensively reflect the relative relationship of chemical components contained in medicinal materials, embody the complexity and correlation of Chinese medicine components, and adapt to the traditional theory of Chinese medicine. It can truly effectively characterize, comprehensively evaluate and comprehensively control the intrinsic quality of Chinese medicine. It is especially suitable for quality control of Chinese medicinal materials and Chinese medicine products when the effective ingredients are not completely clear or do not need to be completely clear. In addition to being used to investigate the origin, harvesting season, harvesting part, processing, storage time and other factors of Chinese medicinal materials, so as to provide a basis for identifying the authenticity and quality of raw medicinal materials before production, Chinese medicine fingerprint can also be used for quality control of Chinese medicine production process: tracking the changes of certain chemical components in preparations, monitoring the consistency and stability of quality between raw medicinal materials and finished products, and between batches of finished products. Compared with the quality analysis method of determining the content of index components, fingerprint spectrum can more comprehensively reflect the types and quantities of chemical components of traditional Chinese medicine. At the current situation where the effective ingredients of traditional Chinese medicine compound preparations have not been fully elucidated, it can realize the comprehensive evaluation of the intrinsic quality of traditional Chinese medicine and the effective control of its overall substance. It is one of the effective means of quality control of traditional Chinese medicine and its preparations.
[0005] At present, there is no literature report on a comprehensive analysis and fingerprint study of the chemical components of the traditional Chinese medicine compound comprising Rehmannia root, Cornus officinalis and Lycium barbarum claimed for protection by the present invention. In the prior art, only a single component in the traditional Chinese medicine compound is analyzed for quality, and there is no comprehensive and systematic quality control method to reflect the quality status of the main reference sample components in the traditional Chinese medicine compound and the finished product of the present invention, and it is impossible to effectively control its production process and product quality, and it is impossible to better guarantee its clinical efficacy. Therefore, it is necessary to adopt a fingerprint quality control method that can comprehensively control the overall quality of the traditional Chinese medicine compound of the present invention to control its key quality. Summary of the invention
[0006] Based on this, the present invention provides a detection method for a traditional Chinese medicine composition containing Rehmannia root, Cornus officinalis and Lycium barbarum. The detection method comprises the following steps: taking a test solution and a reference solution of the traditional Chinese medicine composition for detection, and the chromatographic conditions of the detection are: a chromatographic column with octadecyl bonded silica gel as filler, a mobile phase A selected from one or more of acetonitrile, methanol and tetrahydrofuran, a mobile phase B is acid water, an alkaline aqueous solution and / or a buffered saline solution, and the gradient elution program is: 0-15min, 5% A; 15-25min, 5%→8% A; 25-40min, 8%→12% A; 40-50min, 12%→22% A; 50-6 5min, 22%→30%A; 65-80min, 30%→60%A; 80-90min, 60%→70%A; 90-91min, 70%→5%A; 91-100min, 5%A; the flow rate is 0.5-1.5mL / min, the column temperature is 20-40°C, the detection wavelength is 200-300nm, and the injection volume is 5-15μl; according to the test results, the component information of the traditional Chinese medicine composition, or the component information and content information, is obtained; wherein the traditional Chinese medicine composition comprises rehmannia root, yam, wolfberry, liquorice, tuckahoe and cornus officinalis, and the reference substance comprises ammonium glycyrrhizinate, liquiritin, morroniside and loganin.
[0007] Furthermore, the information is calculated according to the external standard method based on the corresponding peak areas in the recorded chromatogram of the test solution of the Chinese medicine composition and the chromatogram of the reference solution, and the content of one or more of the following ingredients in the Chinese medicine composition: Rehmannia root, yam, wolfberry, liquorice, Poria cocos and Cornus officinalis.
[0008] Furthermore, the preparation method of the Chinese medicine composition test solution includes: measuring an appropriate amount of the Chinese medicine composition solution and adding it into a container, adding a solvent to dilute it, shaking it well, filtering it, and taking the filtrate to obtain the Chinese medicine composition test solution.
[0009] Furthermore, the container is a measuring bottle.
[0010] Furthermore, the solvent is an alcohol, such as methanol.
[0011] Furthermore, the volume / volume (ml / ml) ratio between the Chinese medicine composition solution and the solvent is 0.5-5, for example, about 1.
[0012] Furthermore, the volume of the Chinese medicine composition decoction is 1-10 ml, for example, about 5 ml.
[0013] Furthermore, the preparation method of the reference solution includes: weighing appropriate amounts of ammonium glycyrrhizinate, liquiritin, morroniside and loganin reference substances, adding methanol solution to prepare the reference solution with concentrations of ammonium glycyrrhizinate, liquiritin, morroniside and loganin of 5 to 400 μg / ml respectively.
[0014] Furthermore, the reference substance solution is a mixed solution of about 79.15 μg / ml of ammonium glycyrrhizinate, about 78.68 μg / ml of liquiritin, about 86.45 μg / ml of morroniside, and about 83.16 μg / ml of loganin.
[0015] Furthermore, the flow rate is 0.8-1.2 ml / min, for example, about 1.0 ml / min.
[0016] Furthermore, the column temperature is 25-35°C, for example, about 30°C.
[0017] Furthermore, the detection wavelength is 220-280 nm, for example, 256 nm.
[0018] Furthermore, the injection volume is 8-12 μl, for example, about 10 μl.
[0019] Furthermore, the theoretical plate number of the chromatographic peak corresponding to morroniside is greater than 5,000.
[0020] Furthermore, the separation degree of the chromatographic peaks corresponding to the reference substance is greater than 1.5.
[0021] Furthermore, the chromatographic column is an Agilent 5TC-C18(2)SN:723803 chromatographic column.
[0022] Furthermore, the specifications of the chromatographic column are: column length 250 mm, inner diameter 4.6 mm, particle size 5 μm.
[0023] Furthermore, the mobile phase A is acetonitrile.
[0024] Further, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution are selected from one or more of weak acids and their salts, weak bases and their salts of different concentrations. Further, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution are selected from formic acid, glacial acetic acid, phosphoric acid, trifluoroacetic acid, formic acid and ammonium formate, acetic acid and sodium acetate, acetic acid and ammonium acetate, disodium hydrogen phosphate and sodium dihydrogen phosphate, disodium hydrogen phosphate and potassium dihydrogen phosphate, disodium hydrogen phosphate and citric acid, citric acid and sodium citrate, glycine and hydrochloric acid, or phthalic acid and hydrochloric acid of different concentrations. Further, the acid aqueous solution is an acid aqueous solution of 0.08% to 0.12%. Further, the acid aqueous solution is an aqueous phosphoric acid solution of 0.08% to 0.12%. Further, the acid aqueous solution is an aqueous phosphoric acid solution of about 0.1%. Further, the buffered saline solution is an aqueous phosphate solution and / or an acetate solution. Further, the pH value of the buffered saline solution is not greater than 7.0.
[0025] Furthermore, the preparation method of the Chinese medicine composition solution comprises: (a) weighing an appropriate amount of the Chinese medicine composition, adding a first water for soaking, decocting for a first time until boiling over high heat, then continuing to decoct for a period of time, filtering, and obtaining a medicinal residue and a first medicinal decoction, (b) adding a second water to the medicinal residue, decocting for a second time over high heat until boiling, then changing to a slow heat for decocting, filtering, and obtaining a second medicinal decoction, and (c) combining the first medicinal decoction and the second medicinal decoction to obtain the Chinese medicine composition solution.
[0026] Furthermore, the water is purified water or distilled water.
[0027] Furthermore, the mass / volume ratio between the Chinese medicine composition and the first water is 0.05-1, such as about 0.1.
[0028] Furthermore, the mass / volume ratio between the Chinese medicine composition and the second water is 0.05-1, for example, about 0.125.
[0029] Furthermore, the first water soaking time is 10 to 60 minutes, for example, about 30 minutes.
[0030] Furthermore, the decocting period is 10 to 90 minutes, for example, about 50 minutes.
[0031] Furthermore, the slow-cooking time is 10 to 90 minutes, for example, about 40 minutes.
[0032] Furthermore, in the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis is (1-10):(1-10):(1-10):(1-10):(1-10):(1-10).
[0033] Further, in the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis is about 6.5: about 6.0: about 6.0: about 3.0: about 4.5: about 4.0.
[0034] Furthermore, the Rehmannia root is Rehmannia root prepared.
[0035] Furthermore, the licorice is roasted licorice.
[0036] According to another aspect of the present invention, there is provided a method for constructing a fingerprint of a traditional Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum, the method comprising the following steps:
[0037] Preparation of the test solution: measure an appropriate amount of the Chinese medicine composition solution and add it into a container, add a solvent to dilute it, shake it evenly, filter it, and take the filtrate to obtain the Chinese medicine composition test solution; wherein the Chinese medicine composition includes Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis.
[0038] Preparation of reference solution: Weigh appropriate amounts of ammonium glycyrrhizinate, liquiritin, morroniside and loganin reference substances, add methanol solution to prepare reference solutions with concentrations of ammonium glycyrrhizinate, liquiritin, morroniside and loganin of 5 to 400 μg / ml, respectively.
[0039] According to the results of high performance liquid chromatography detection of the test solution and the reference solution, a fingerprint of the traditional Chinese medicine composition is obtained.
[0040] The chromatographic conditions for high performance liquid phase detection are as follows: a chromatographic column with octadecyl bonded silica gel as filler is used, mobile phase A is selected from one or more of acetonitrile, methanol and tetrahydrofuran, mobile phase B is acid water, alkaline aqueous solution and / or buffered saline solution, and the gradient elution program is as follows: 0-15 min, 5% A; 15-25 min, 5%→8% A; 25-40 min, 8%→12% A; 40-50 min, 12%→22% A; 50-65 min, 22%→30% A; 65-80 min, 30%→60% A; 80-90 min, 60%→70% A; 90-91 min, 70%→5% A; 91-100 min, 5% A; the flow rate is 0.5-1.5 mL / min, the column temperature is 20-40° C., the detection wavelength is 200-300 nm, and the injection volume is 5-15 μl.
[0041] Furthermore, in the preparation of the test solution of the traditional Chinese medicine composition, the solvent is an alcohol, such as methanol.
[0042] Furthermore, the container is a measuring bottle.
[0043] Furthermore, the volume / volume (ml / ml) ratio between the Chinese medicine composition solution and the solvent is 0.5-5, for example, about 1.
[0044] Furthermore, the volume of the Chinese medicine composition solution is 1-10 ml, for example, about 5 ml.
[0045] Furthermore, the flow rate is 0.8-1.2 ml / min, for example, about 1.0 mL / min.
[0046] Furthermore, the column temperature is 25-35°C, for example, about 30°C.
[0047] Furthermore, the detection wavelength is 220-280 nm, for example, 256 nm.
[0048] Furthermore, the injection volume is 8-12 μl, for example, about 10 μl.
[0049] Furthermore, the reference substance solution is a mixed solution of about 79.15 μg / ml of ammonium glycyrrhizinate, about 78.68 μg / ml of liquiritin, about 86.45 μg / ml of morroniside, and about 83.16 μg / ml of loganin.
[0050] Furthermore, the theoretical plate number of the chromatographic peak corresponding to morroniside is greater than 5,000.
[0051] Furthermore, the separation degree of the chromatographic peaks corresponding to the reference substance is greater than 1.5.
[0052] Furthermore, the chromatographic column is an Agilent 5TC-C18(2)SN:723803 chromatographic column.
[0053] Furthermore, the specifications of the chromatographic column are: column length 250 mm, inner diameter 4.6 mm, particle size 5 μm.
[0054] Furthermore, the mobile phase A is acetonitrile.
[0055] Further, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution are selected from one or more of weak acids and their salts, weak bases and their salts of different concentrations. Further, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution are selected from formic acid, glacial acetic acid, phosphoric acid, trifluoroacetic acid, formic acid and ammonium formate, acetic acid and sodium acetate, acetic acid and ammonium acetate, disodium hydrogen phosphate and sodium dihydrogen phosphate, disodium hydrogen phosphate and potassium dihydrogen phosphate, disodium hydrogen phosphate and citric acid, citric acid and sodium citrate, glycine and hydrochloric acid, or phthalic acid and hydrochloric acid of different concentrations. Further, the acid aqueous solution is 0.08% to 0.12% acid aqueous solution. Further, the acid aqueous solution is 0.08% to 0.12% phosphoric acid aqueous solution, formic acid aqueous solution or glacial acetic acid aqueous solution. Further, the acid aqueous solution is about 0.1% phosphoric acid aqueous solution. Further, the buffered saline solution is phosphate aqueous solution and / or acetate aqueous solution. Further, the pH value of the buffered saline solution is not greater than 7.0.
[0056] Furthermore, the preparation method of the Chinese medicine composition solution comprises: (a) weighing an appropriate amount of the Chinese medicine composition, adding a first water for soaking, decocting for a first time until boiling over high heat, then continuing to decoct for a period of time, filtering, and obtaining a medicinal residue and a first medicinal decoction, (b) adding a second water to the medicinal residue, decocting for a second time over high heat until boiling, then changing to a slow heat for decocting, filtering, and obtaining a second medicinal decoction, and (c) combining the first medicinal decoction and the second medicinal decoction to obtain the Chinese medicine composition solution.
[0057] Furthermore, the water is purified water or distilled water.
[0058] Furthermore, the mass / volume ratio between the Chinese medicine composition and the first water is 0.05-1, such as about 0.1.
[0059] Furthermore, the mass / volume ratio between the Chinese medicine composition and the second water is 0.05-1, for example, about 0.125.
[0060] Furthermore, the first water soaking time is 10 to 60 minutes, for example, about 30 minutes.
[0061] Furthermore, the decocting period is 10 to 90 minutes, for example, about 50 minutes.
[0062] Furthermore, the slow-cooking time is 10 to 90 minutes, for example, about 40 minutes.
[0063] Furthermore, in the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis is (1-10):(1-10):(1-10):(1-10):(1-10):(1-10).
[0064] Further, in the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis is about 6.5: about 6.0: about 6.0: about 3.0: about 4.5: about 4.0.
[0065] Furthermore, the Rehmannia root is Rehmannia root prepared.
[0066] Furthermore, the licorice is roasted licorice.
[0067] Furthermore, when the detection wavelength is 256nm, the fingerprint spectrum includes peaks 1-15, among which peak 1 belongs to the medicinal flavor of Rehmannia and Lycium barbarum; peaks 2 and 3 belong to the medicinal flavor of Rehmannia; peaks 4 and 12 belong to the medicinal flavor of Licorice and Cornus officinalis; peaks 5, 7, 9 and 10 belong to the medicinal flavor of Cornus officinalis; peak 6 belongs to the medicinal flavor of Lycium barbarum; peaks 8, 11, 13, 14 and 15 belong to the medicinal flavor of Licorice.
[0068] Further, when the detection wavelength is 256 nm, the retention times of peaks 1-15 are 10.598±10%, 11.697±10%, 16.986±10%, 31.422±10%, 32.835±10%, 35.948±10%, 45.854±10%, 53.890±10%, 54.412±10%, 58.003±10%, 62.713±10%, 72.479±10%, 73.793±10%, 75.839±10% and 77.132±10%, respectively.
[0069] Further, the peak No. 5 is the chromatographic peak of morroniside. Further, the peak No. 7 is the chromatographic peak of loganin. Further, the peak No. 8 is the chromatographic peak of liquiritin. Further, the peak No. 15 is the chromatographic peak of ammonium glycyrrhizinate.
[0070] Furthermore, the fingerprint spectrum includes 15 characteristic chromatographic peaks at a detection wavelength of 256 nm, with the chromatographic peak of peak 5, morroniside, as the reference peak, and the relative retention times of the other 14 characteristic chromatographic peaks are peak 1 0.3228±10%, peak 2 0.3562±10%, peak 3 0.5173±10%, peak 4 0.9570±10%, peak 6 1.0948±10%, peak 7 1.1047±10%, peak 8 1.0004±10%, peak 9 1.0004±10%, peak 10 1.0004±10%, peak 11 1.0004±10%, peak 12 1.0004±10%, peak 13 1.0004±10%, peak 14 1.0004±10%, peak 15 1.0004±10%, peak 16 1.0004±10%, peak 17 1.0004±10%, peak 18 0%, peak 7 1.3965±10%, peak 8 1.6413±10%, peak 9 1.6572±10%, peak 10 1.7666±10%, peak 11 1.9100±10%, peak 12 2.2074±10%, peak 13 2.2475±10%, peak 14 2.3098±10% and peak 15 2.3492±10%.
[0071] According to another aspect of the present invention, a quality control method for a traditional Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum is provided, the quality control method comprising the following steps: (1) establishing a standard fingerprint of a reference sample of the traditional Chinese medicine composition according to the fingerprint construction method; (2) taking a test solution of the traditional Chinese medicine composition and testing it according to the chromatographic conditions in the fingerprint construction method to obtain a fingerprint of a test sample of the traditional Chinese medicine composition; and (3) comparing the fingerprint of the test sample of the traditional Chinese medicine composition obtained in step (2) with the standard fingerprint of the reference sample of the traditional Chinese medicine composition obtained in step (1); a product that meets the requirements is a qualified product, and a product that does not meet the requirements is an unqualified product.
[0072] Furthermore, the compliance requirements include one or more of the following: (1) the fingerprint of the Chinese medicine composition sample to be tested presents 15 characteristic chromatographic peaks, and the retention time of each characteristic chromatographic peak is within ±10% of the retention time value of the corresponding reference chromatographic peak in the standard fingerprint of the Chinese medicine composition benchmark sample; (2) taking the chromatographic peak of morroniside as the S peak, the relative retention time of each characteristic chromatographic peak in the fingerprint of the Chinese medicine composition sample to be tested and the S peak is within ±10% of the relative retention time value of each characteristic chromatographic peak in the standard fingerprint of the Chinese medicine composition benchmark sample; and (3) according to the Chinese medicine chromatographic fingerprint similarity evaluation system, the similarity between the fingerprint of the Chinese medicine composition sample to be tested and the standard fingerprint of the Chinese medicine composition benchmark sample shall not be less than 0.90 after similarity calculation.
[0073] According to another aspect of the present invention, there is provided a use of the above detection method, the above construction method or the above quality control method in quality detection, quality evaluation or quality control of a traditional Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum.
[0074] Beneficial effects of the present invention:
[0075] In short, the present invention provides a fingerprint spectrum determination and quality control method for a traditional Chinese medicine compound reference sample containing Rehmannia root, Cornus officinalis and Lycium barbarum. The method confirms 15 common characteristic peaks, has simple conditions and short analysis time, solves the problems of difficulty in separating fingerprint characteristic peaks and interference from impurity peaks, ensures the chemical composition stability and safety of use of the reference sample, provides an important reference basis for the quality control of subsequent preparations, ensures the stable quality of the product, guarantees the efficacy of the traditional Chinese medicine compound, and allows the traditional Chinese medicine compound to better serve human life and health.
[0076] Specifically, compared with the prior art, the present invention has the following beneficial effects: (1) Establishing the fingerprint of the traditional Chinese medicine compound reference sample of the present invention overcomes the defect that the determination of the content of a single component is difficult to reflect the overall content, and can control the intrinsic quality of the traditional Chinese medicine compound reference sample of the present invention from a holistic and macroscopic perspective, thereby ensuring the efficacy of the drug, and using the main means of modern drug research to achieve the inheritance of fine products to classics, so that classic prescriptions are more formally controlled in terms of quality; (2) The chemical components in the traditional Chinese medicine compound reference sample of the present invention are complex, and it is difficult to separate its characteristic peaks. In the process of establishing the fingerprint, the present invention adopts a gradient elution method to solve the problem of difficulty in separating the fingerprint characteristic peaks and interference from impurity peaks; (3) In the process of establishing the fingerprint of the traditional Chinese medicine compound reference sample of the present invention, the present invention , 15 common characteristic peaks were confirmed, and their relative retention time, relative peak area and similarity were studied, which ensured the chemical composition stability and safety of the reference sample, and provided an important reference basis and quality reference for the quality control of the subsequent compound preparations; (4) The fingerprint spectrum of each effective ingredient in the traditional Chinese medicine compound reference sample of the present invention was regarded as a whole, and the sequence and relationship of each characteristic peak were emphasized, which not only avoided the one-sidedness of judging the overall quality of the traditional Chinese medicine compound reference sample of the present invention due to only measuring one or two chemical components, but also reduced the possibility of artificial processing for quality compliance, and provided a new method and means for completely and accurately evaluating the quality of the traditional Chinese medicine compound reference sample of the present invention; (5) The method of the present invention has good stability, high precision, good reproducibility, convenience and easy to master. BRIEF DESCRIPTION OF THE DRAWINGS
[0077] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without exceeding the scope of protection required by the present invention.
[0078] Figure 1 This is the reference fingerprint of the test solution of the Chinese medicine compound decoction of the present application. Among them, peak 5 is morroniside, peak 7 is loganin, peak 8 is liquiritin, and peak 15 is ammonium glycyrrhizinate. In addition, peak 1 belongs to the medicinal flavor of Rehmannia glutinosa and Lycium barbarum; peaks 2 and 3 belong to the medicinal flavor of Rehmannia glutinosa; peaks 4 and 12 belong to the medicinal flavor of Licorice and Cornus officinalis; peaks 5, 7, 9 and 10 belong to the medicinal flavor of Cornus officinalis; peak 6 belongs to the medicinal flavor of Lycium barbarum; peaks 8, 11, and peaks 13 to 15 belong to the medicinal flavor of Licorice.
[0079] Figure 2 These are the fingerprints of 15 batches of decoctions of the Chinese herbal compound decoctions of this application. DETAILED DESCRIPTION
[0080] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.
[0081] Unless otherwise indicated, all technical and scientific terms and abbreviations used herein have the meanings commonly understood by those of ordinary skill in the field of the invention or the field in which the terms are used. Although any methods, conditions, substances or materials similar to or equivalent to those disclosed herein may be used in the practice of the present invention, preferred methods, conditions, substances or materials are described herein.
[0082] The present invention is intended to encompass all alternatives, variations and equivalents that may be included in the present invention as defined by the claims. Those skilled in the art will recognize many methods and materials similar or equivalent to those described herein that can be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described.
[0083] As used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0084] In the present invention, the term "comprising" is synonymous with "including". As used herein, the terms "comprising", "including", "having", "containing" or any other variation thereof are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus comprising the listed elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
[0085] As described in the background technology section, there is no literature report on the comprehensive analysis and fingerprint study of the chemical components of the Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum claimed by the present invention. In order to solve the above problems, the present invention provides a method for detecting a Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum, the detection method comprising the following steps: taking a test solution and a reference solution of the Chinese medicine composition for detection, the chromatographic conditions of the detection are: using a chromatographic column with octadecyl bonded silica gel as filler, mobile phase A is selected from one or more of acetonitrile, methanol and tetrahydrofuran, mobile phase B is acid water, alkaline aqueous solution and / or buffered saline solution, and the gradient elution program is: 0-15min, 5% A; 15-25min, 5%→8% A; 25-40min, 8%→12% A; 40-50min, 12%→22% A; 5 0-65min, 22%→30%A; 65-80min, 30%→60%A; 80-90min, 60%→70%A; 90-91min, 70%→5%A; 91-100min, 5%A; flow rate is 0.5-1.5mL / min, column temperature is 20-40°C, detection wavelength is 200-300nm, injection volume is 5-15μl; according to the test results, the component information, or the component information and content information of the traditional Chinese medicine composition are obtained; wherein the traditional Chinese medicine composition includes rehmannia root, yam, wolfberry, liquorice, tuckahoe and cornus officinalis, and the reference substance includes ammonium glycyrrhizinate, liquiritin, morroniside and loganin.
[0086] In the present invention, when time, flow rate, column temperature, wavelength, injection amount, ratio, volume, concentration, or other values or parameters are expressed as ranges, preferred ranges, or ranges defined by a series of upper preferred values and lower preferred values, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value with any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when the range "20-40" is disclosed, the described range should be interpreted as including the range "20-40", "20-35", "20-30", "20-25", "25-40", "25-35", "25-30", "30-40", "30-35", "35-40", etc. When a numerical range is described herein, unless otherwise stated, the range is intended to include its end values and all integers and fractions within the range.
[0087] In a preferred embodiment, the information is the content of one or more of the following ingredients in the Chinese medicine composition calculated according to the external standard method based on the corresponding peak areas in the recorded chromatogram of the test solution of the Chinese medicine composition and the chromatogram of the reference solution: Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis.
[0088] In a preferred embodiment, the preparation method of the Chinese medicine composition test solution includes: measuring an appropriate amount of the Chinese medicine composition solution and adding it to a container, adding a solvent to dilute it, shaking it well, filtering it, and taking the filtrate to obtain the Chinese medicine composition test solution.
[0089] In a preferred embodiment, the container is a measuring bottle.
[0090] In a preferred embodiment, the solvent is an alcohol, such as methanol.
[0091] In a preferred embodiment, the volume / volume (ml / ml) ratio between the Chinese medicine composition solution and the solvent is 0.5-5, such as about 1.
[0092] In the present invention, "about" refers to a value within the range of ±5% of a specific value. For example, "about 1" includes ±5% of 1, or from 0.95 to 1.05.
[0093] In a preferred embodiment, the volume of the Chinese medicine composition decoction is 1-10 ml, for example, about 5 ml.
[0094] In the present invention, "about" refers to a value within a range of ±5% of a particular value. For example, "about 5" includes ±5% of 5, or from 4.75 to 5.25.
[0095] In a preferred embodiment, the preparation method of the reference solution comprises: weighing appropriate amounts of ammonium glycyrrhizinate, liquiritin, morroniside and loganin reference substances, adding methanol solution to prepare the reference solution with a concentration of ammonium glycyrrhizinate, liquiritin, morroniside and loganin of 5 to 400 μg / ml respectively.
[0096] In a preferred embodiment, the reference substance solution is a mixed solution of about 79.15 μg / ml of ammonium glycyrrhizinate, about 78.68 μg / ml of liquiritin, about 86.45 μg / ml of morroniside, and about 83.16 μg / ml of loganin.
[0097] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 79.15" includes ±5% of 79.15, or from 75.1925 to 83.1075; "about 78.68" includes ±5% of 78.68, or from 74.746 to 82.614; "about 86.45" includes ±5% of 86.45, or from 82.1275 to 90.7725; "about 83.16" includes ±5% of 83.16, or from 79.002 to 87.318.
[0098] In a preferred embodiment, the flow rate is 0.8-1.2 ml / min, such as about 1.0 ml / min.
[0099] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 1.0" includes ±5% of 1.0, or from 0.95 to 1.05.
[0100] In a preferred embodiment, the column temperature is 25-35°C, such as about 30°C.
[0101] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 30" includes ±5% of 30, or from 28.5 to 31.5.
[0102] In a preferred embodiment, the detection wavelength is 220-280 nm, for example, 256 nm.
[0103] In a preferred embodiment, the injection volume is 8-12 μl, such as about 10 μl.
[0104] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 10" includes ±5% of 10, or from 9.5 to 10.5.
[0105] In a preferred embodiment, the theoretical plate number of the chromatographic peak corresponding to morroniside is greater than 5,000.
[0106] In a preferred embodiment, the separation degree of the chromatographic peaks corresponding to the reference substance is greater than 1.5.
[0107] In a preferred embodiment, the chromatographic column is an Agilent 5TC-C18(2)SN:723803 chromatographic column.
[0108] In a preferred embodiment, the specifications of the chromatographic column are: column length 250 mm, inner diameter 4.6 mm, particle size 5 μm.
[0109] In a preferred embodiment, the mobile phase A is acetonitrile.
[0110] In a preferred embodiment, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution are selected from one or more of weak acids and their salts, weak bases and their salts of different concentrations. In a preferred embodiment, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution are selected from formic acid, glacial acetic acid, phosphoric acid, trifluoroacetic acid, formic acid and ammonium formate, acetic acid and sodium acetate, acetic acid and ammonium acetate, disodium hydrogen phosphate and sodium dihydrogen phosphate, disodium hydrogen phosphate and potassium dihydrogen phosphate, disodium hydrogen phosphate and citric acid, citric acid and sodium citrate, glycine and hydrochloric acid, or phthalic acid and hydrochloric acid of different concentrations. In a preferred embodiment, the acid aqueous solution is an acid aqueous solution of 0.08% to 0.12%. In a preferred embodiment, the acid aqueous solution is an aqueous solution of 0.08% to 0.12% phosphoric acid. In a preferred embodiment, the acid aqueous solution is an aqueous solution of about 0.1% phosphoric acid.
[0111] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 0.1%" includes ±5% of 0.1%, or from 0.095% to 0.105%.
[0112] In a preferred embodiment, the buffered saline solution is a phosphate solution and / or an acetate solution. In a preferred embodiment, the pH value of the buffered saline solution is not greater than 7.0.
[0113] In a preferred embodiment, the preparation method of the Chinese medicine composition solution comprises: (a) weighing an appropriate amount of the Chinese medicine composition, adding a first water for soaking, decocting for a first time with high heat until boiling, then continuing to decoct for a period of time, filtering, and obtaining a medicinal residue and a first medicinal decoction, (b) adding a second water to the medicinal residue, decocting for a second time with high heat until boiling, then changing to a slow heat for decoction, filtering, and obtaining a second medicinal decoction, and (c) combining the first medicinal decoction and the second medicinal decoction to obtain the Chinese medicine composition solution.
[0114] In a preferred embodiment, the water is purified water or distilled water.
[0115] In a preferred embodiment, the mass / volume ratio between the traditional Chinese medicine composition and the first water is 0.05-1, such as about 0.1.
[0116] In the present invention, "about" refers to a value within the range of ±5% of a specific value. For example, "about 0.1" includes ±5% of 0.1, or from 0.095 to 0.105.
[0117] In a preferred embodiment, the mass / volume ratio between the traditional Chinese medicine composition and the second water is 0.05-1, for example, about 0.125.
[0118] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 0.125" includes ±5% of 0.125, or from 0.11875 to 0.13125.
[0119] In a preferred embodiment, the first water soaking time is 10 to 60 minutes, such as about 30 minutes.
[0120] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 30" includes ±5% of 30, or from 28.5 to 31.5.
[0121] In a preferred embodiment, the decocting period is 10 to 90 minutes, for example, about 50 minutes.
[0122] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 50" includes ±5% of 50, or from 47.5 to 52.5.
[0123] In a preferred embodiment, the slow-cooking time is 10 to 90 minutes, such as about 40 minutes.
[0124] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 40" includes ±5% of 40, or from 38 to 42.
[0125] In a preferred embodiment, in the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis is (1-10):(1-10):(1-10):(1-10):(1-10):(1-10).
[0126] In a preferred embodiment, in the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Dioscorea opposita, Lycium barbarum, Licorice root, Poria cocos and Cornus officinalis is about 6.5: about 6.0: about 6.0: about 3.0: about 4.5: about 4.0.
[0127] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 6.5" includes ±5% of 6.5, or from 6.175 to 6.825; "about 6.0" includes ±5% of 6.0, or from 5.7 to 6.3; "about 3.0" includes ±5% of 3.0, or from 2.85 to 3.15; "about 4.5" includes ±5% of 4.5, or from 4.275 to 4.725; "about 4.0" includes ±5% of 4.0, or from 3.8 to 4.2.
[0128] In a preferred embodiment, the Rehmannia root is Rehmannia root prepared.
[0129] In a preferred embodiment, the licorice is roasted licorice.
[0130] According to another aspect of the present invention, there is provided a method for constructing a fingerprint of a traditional Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum, the method comprising the following steps:
[0131] Preparation of the test solution: measure an appropriate amount of the Chinese medicine composition solution and add it into a container, add a solvent to dilute it, shake it evenly, filter it, and take the filtrate to obtain the Chinese medicine composition test solution; wherein the Chinese medicine composition includes Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis.
[0132] Preparation of reference solution: Weigh appropriate amounts of ammonium glycyrrhizinate, liquiritin, morroniside and loganin reference substances, add methanol solution to prepare reference solutions with concentrations of ammonium glycyrrhizinate, liquiritin, morroniside and loganin of 5 to 400 μg / ml, respectively.
[0133] According to the results of high performance liquid chromatography detection of the test solution and the reference solution, a fingerprint of the traditional Chinese medicine composition is obtained.
[0134] The chromatographic conditions for high performance liquid phase detection are as follows: a chromatographic column with octadecyl bonded silica gel as filler is used, mobile phase A is selected from one or more of acetonitrile, methanol and tetrahydrofuran, mobile phase B is acid water, alkaline aqueous solution and / or buffered saline solution, and the gradient elution program is as follows: 0-15 min, 5% A; 15-25 min, 5%→8% A; 25-40 min, 8%→12% A; 40-50 min, 12%→22% A; 50-65 min, 22%→30% A; 65-80 min, 30%→60% A; 80-90 min, 60%→70% A; 90-91 min, 70%→5% A; 91-100 min, 5% A; the flow rate is 0.5-1.5 mL / min, the column temperature is 20-40° C., the detection wavelength is 200-300 nm, and the injection volume is 5-15 μl.
[0135] In a preferred embodiment, in the preparation of the test solution of the traditional Chinese medicine composition, the solvent is alcohol, such as methanol.
[0136] In a preferred embodiment, the container is a measuring bottle.
[0137] In a preferred embodiment, the volume / volume (ml / ml) ratio between the Chinese medicine composition solution and the solvent is 0.5-5, such as about 1.
[0138] In the present invention, "about" refers to a value within the range of ±5% of a specific value. For example, "about 1" includes ±5% of 1, or from 0.95 to 1.05.
[0139] In a preferred embodiment, the volume of the Chinese medicine composition solution is 1-10 ml, for example, about 5 ml.
[0140] In the present invention, "about" refers to a value within a range of ±5% of a particular value. For example, "about 5" includes ±5% of 5, or from 4.75 to 5.25.
[0141] In a preferred embodiment, the flow rate is 0.8-1.2 ml / min, such as about 1.0 mL / min.
[0142] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 1.0" includes ±5% of 1.0, or from 0.95 to 1.05.
[0143] In a preferred embodiment, the column temperature is 25-35°C, such as about 30°C.
[0144] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 30" includes ±5% of 30, or from 28.5 to 31.5.
[0145] In a preferred embodiment, the detection wavelength is 220-280 nm, for example, 256 nm.
[0146] In a preferred embodiment, the injection volume is 8-12 μl, such as about 10 μl.
[0147] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 10" includes ±5% of 10, or from 9.5 to 10.5.
[0148] In a preferred embodiment, the reference substance solution is a mixed solution of about 79.15 μg / ml of ammonium glycyrrhizinate, about 78.68 μg / ml of liquiritin, about 86.45 μg / ml of morroniside, and about 83.16 μg / ml of loganin.
[0149] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 79.15" includes ±5% of 79.15, or from 75.1925 to 83.1075; "about 78.68" includes ±5% of 78.68, or from 74.746 to 82.614; "about 86.45" includes ±5% of 86.45, or from 82.1275 to 90.7725; "about 83.16" includes ±5% of 83.16, or from 79.002 to 87.318.
[0150] In a preferred embodiment, the theoretical plate number of the chromatographic peak corresponding to morroniside is greater than 5,000.
[0151] In a preferred embodiment, the separation degree of the chromatographic peaks corresponding to the reference substance is greater than 1.5.
[0152] In a preferred embodiment, the chromatographic column is an Agilent 5TC-C18(2)SN:723803 chromatographic column.
[0153] In a preferred embodiment, the specifications of the chromatographic column are: column length 250 mm, inner diameter 4.6 mm, particle size 5 μm.
[0154] In a preferred embodiment, the mobile phase A is acetonitrile.
[0155] In a preferred embodiment, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution are selected from one or more of weak acids and their salts, weak bases and their salts of different concentrations. In a preferred embodiment, the acid aqueous solution, alkali aqueous solution and / or buffered saline solution are selected from formic acid, glacial acetic acid, phosphoric acid, trifluoroacetic acid, formic acid and ammonium formate, acetic acid and sodium acetate, acetic acid and ammonium acetate, disodium hydrogen phosphate and sodium dihydrogen phosphate, disodium hydrogen phosphate and potassium dihydrogen phosphate, disodium hydrogen phosphate and citric acid, citric acid and sodium citrate, glycine and hydrochloric acid, or phthalic acid and hydrochloric acid of different concentrations. In a preferred embodiment, the acid aqueous solution is an acid aqueous solution of 0.08% to 0.12%. In a preferred embodiment, the acid aqueous solution is an aqueous phosphoric acid solution, an aqueous formic acid solution or an aqueous glacial acetic acid solution of 0.08% to 0.12%.
[0156] In a preferred embodiment, the aqueous acid solution is about 0.1% phosphoric acid aqueous solution.
[0157] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 0.1%" includes ±5% of 0.1%, or from 0.095% to 0.105%.
[0158] In a preferred embodiment, the buffered saline solution is a phosphate solution and / or an acetate solution. In a preferred embodiment, the pH value of the buffered saline solution is not greater than 7.0.
[0159] In a preferred embodiment, the preparation method of the Chinese medicine composition solution comprises: (a) weighing an appropriate amount of the Chinese medicine composition, adding a first water for soaking, decocting for a first time with high heat until boiling, then continuing to decoct for a period of time, filtering, and obtaining a medicinal residue and a first medicinal decoction, (b) adding a second water to the medicinal residue, decocting for a second time with high heat until boiling, then changing to a slow heat for decoction, filtering, and obtaining a second medicinal decoction, and (c) combining the first medicinal decoction and the second medicinal decoction to obtain the Chinese medicine composition solution.
[0160] In a preferred embodiment, the water is purified water or distilled water.
[0161] In a preferred embodiment, the mass / volume ratio between the traditional Chinese medicine composition and the first water is 0.05-1, such as about 0.1.
[0162] In the present invention, "about" refers to a value within the range of ±5% of a specific value. For example, "about 0.1" includes ±5% of 0.1, or from 0.095 to 0.105.
[0163] In a preferred embodiment, the mass / volume ratio between the traditional Chinese medicine composition and the second water is 0.05-1, for example, about 0.125.
[0164] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 0.125" includes ±5% of 0.125, or from 0.11875 to 0.13125.
[0165] In a preferred embodiment, the first water soaking time is 10 to 60 minutes, such as about 30 minutes.
[0166] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 30" includes ±5% of 30, or from 28.5 to 31.5.
[0167] In a preferred embodiment, the decocting period is 10 to 90 minutes, for example, about 50 minutes.
[0168] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 50" includes ±5% of 50, or from 47.5 to 52.5.
[0169] In a preferred embodiment, the slow-cooking time is 10 to 90 minutes, such as about 40 minutes.
[0170] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 40" includes ±5% of 40, or from 38 to 42.
[0171] In a preferred embodiment, in the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis is (1-10):(1-10):(1-10):(1-10):(1-10):(1-10).
[0172] In a preferred embodiment, in the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Dioscorea opposita, Lycium barbarum, Licorice root, Poria cocos and Cornus officinalis is about 6.5: about 6.0: about 6.0: about 3.0: about 4.5: about 4.0.
[0173] In the present invention, "about" refers to a value within a range of ±5% of a specific value. For example, "about 6.5" includes ±5% of 6.5, or from 6.175 to 6.825; "about 6.0" includes ±5% of 6.0, or from 5.7 to 6.3; "about 3.0" includes ±5% of 3.0, or from 2.85 to 3.15; "about 4.5" includes ±5% of 4.5, or from 4.275 to 4.725; "about 4.0" includes ±5% of 4.0, or from 3.8 to 4.2.
[0174] In a preferred embodiment, the Rehmannia root is Rehmannia root prepared.
[0175] In a preferred embodiment, the licorice is roasted licorice.
[0176] In a preferred embodiment, when the detection wavelength is 256nm, the fingerprint spectrum includes peaks 1-15, wherein peak 1 belongs to the medicinal flavor of Rehmannia root and Lycium barbarum; peaks 2 and 3 belong to the medicinal flavor of Rehmannia root; peaks 4 and 12 belong to the medicinal flavors of Licorice and Cornus officinalis; peaks 5, 7, 9 and 10 belong to the medicinal flavor of Cornus officinalis; peak 6 belongs to the medicinal flavor of Lycium barbarum; peaks 8, 11, 13, 14 and 15 belong to the medicinal flavor of Licorice.
[0177] In a preferred embodiment, when the detection wavelength is 256 nm, the retention times of peaks 1-15 are 10.598±10%, 11.697±10%, 16.986±10%, 31.422±10%, 32.835±10%, 35.948±10%, 45.854±10%, 53.890±10%, 54.412±10%, 58.003±10%, 62.713±10%, 72.479±10%, 73.793±10%, 75.839±10% and 77.132±10%, respectively.
[0178] In a preferred embodiment, the peak No. 5 is the chromatographic peak of morroniside. In a preferred embodiment, the peak No. 7 is the chromatographic peak of loganin. In a preferred embodiment, the peak No. 8 is the chromatographic peak of liquiritin. In a preferred embodiment, the peak No. 15 is the chromatographic peak of ammonium glycyrrhizinate.
[0179] In a preferred embodiment, the fingerprint spectrum includes 15 characteristic chromatographic peaks at a detection wavelength of 256 nm, with the chromatographic peak of peak 5, morroniside, as the reference peak, and the relative retention times of the other 14 characteristic chromatographic peaks are peak 1 0.3228±10%, peak 2 0.3562±10%, peak 3 0.5173±10%, peak 4 0.9570±10%, peak 6 1.09 48±10%, peak 7 1.3965±10%, peak 8 1.6413±10%, peak 9 1.6572±10%, peak 10 1.7666±10%, peak 11 1.9100±10%, peak 12 2.2074±10%, peak 13 2.2475±10%, peak 14 2.3098±10% and peak 15 2.3492±10%.
[0180] According to another aspect of the present invention, a quality control method for a traditional Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum is provided, the quality control method comprising the following steps: (1) establishing a standard fingerprint of a reference sample of the traditional Chinese medicine composition according to the fingerprint construction method; (2) taking a test solution of the traditional Chinese medicine composition and testing it according to the chromatographic conditions in the fingerprint construction method to obtain a fingerprint of a test sample of the traditional Chinese medicine composition; and (3) comparing the fingerprint of the test sample of the traditional Chinese medicine composition obtained in step (2) with the standard fingerprint of the reference sample of the traditional Chinese medicine composition obtained in step (1); a product that meets the requirements is a qualified product, and a product that does not meet the requirements is an unqualified product.
[0181] In a preferred embodiment, the compliance requirements include one or more of the following: (1) the fingerprint of the Chinese medicine composition sample to be tested presents 15 characteristic chromatographic peaks, and the retention time of each characteristic chromatographic peak is within ±10% of the retention time value of the corresponding reference chromatographic peak in the standard fingerprint of the Chinese medicine composition benchmark sample; (2) taking the chromatographic peak of morroniside as the S peak, the relative retention time of each characteristic chromatographic peak in the fingerprint of the Chinese medicine composition sample to be tested and the S peak is within ±10% of the relative retention time value of each characteristic chromatographic peak in the standard fingerprint of the Chinese medicine composition benchmark sample; and (3) according to the Chinese medicine chromatographic fingerprint similarity evaluation system, the similarity between the fingerprint of the Chinese medicine composition sample to be tested and the standard fingerprint of the Chinese medicine composition benchmark sample shall not be less than 0.90 after similarity calculation.
[0182] According to another aspect of the present invention, there is provided a use of the above detection method, the above construction method or the above quality control method in quality detection, quality evaluation or quality control of a traditional Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum.
[0183] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions or conditions recommended by the manufacturer.
[0184] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
[0185] The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in this patent specification can be used in combination with any combination form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.
[0186] Example
[0187] 1. Instruments and test drugs
[0188] Instruments: Agilent 1100 HPLC system, including G1322A degasser, G1311A quaternary pump, G1313A autosampler, G1315B DAD diode array detector, G1316A column oven, ChemStation chromatographic workstation; Agilent 1260 HPLC system, including G1322A degasser, G1311A quaternary pump, G1313A autosampler, G1315B DAD diode array detector, G1316A column oven, ChemStation chromatographic workstation; Waters 2695 HPLC system, including quaternary gradient infusion pump (Alliance 2695), 120-position high-performance autosampler, imported column oven, Waters 2996 DAD diode array detector, Empower 3Chromatographic management system; Electronic analytical balance: SHIMADZU
[0189] AUW120D, Sartorius BSA124S, JY2002; Ultrasonic cleaning machine: KQ-500DB, Kunshan Ultrasonic Instrument Co., Ltd.; Ultrapure water machine: AXLK1820-2, Asura Chongqing Asura Technology Development Co., Ltd.; Chromatographic columns: Column 1: Agilent 5TC-C18 (2) (4.6×250mm, 5μm) SN: 723746); Column 2: Agilent 5TC-C18 (2) (4.6×250mm, 5μm) SN: 723803); Column 3: Agilent 5TC-C18 (2) (4.6×250mm, 5μm) SN: 730900); Methanol was chromatographically pure, phosphoric acid was premium pure, methanol was analytically pure, and water was ultrapure water.
[0190] Reference substance information: Morroniside (batch number 111998-202205, content 98.4%, China Food and Drug Inspection Institute); Loganin (batch number 111640-201808, content 99.0%, China Food and Drug Inspection Institute); Licorice glycoside (batch number 111610-202209, content 95.2%, China Food and Drug Inspection Institute); Ammonium glycyrrhizinate (batch number 110731-202122, content 94.4%, China Food and Drug Inspection Institute).
[0191] 2. Solution preparation
[0192] 2.1. Preparation of reference solution
[0193] Accurately weigh ammonium glycyrrhizinate, liquiritin, morroniside, and loganin, add methanol to dissolve, and prepare mixed reference solutions of 0.07915 mg / ml, 0.07868 mg / ml, 0.08645 mg / ml, and 0.08316 mg / ml, respectively.
[0194] 2.2 Preparation of test solution
[0195] Take 6.5g of Rehmannia glutinosa (steamed), 6.0g of Chinese yam, 6.0g of Chinese wolfberry, 3.0g of roasted licorice root, 4.5g of Poria cocos, and 4.0g of Cornus officinalis, add 10 times the amount of water, and soak for 30 minutes. Boil over high heat and continue to decoct for 50 minutes, and filter out the liquid. Decoction for the second time, add 8 times the amount of water, decoct over high heat until boiling, then simmer over low heat for 40 minutes, and filter out the liquid. Combine the filtrates from the two decoctions to obtain the product.
[0196] Preparation of test solution: Accurately measure 5 ml of the reference substance and place it in a 10 ml volumetric flask, add methanol to dilute to the scale, shake well, filter, and take the filtrate to obtain the test solution.
[0197] 2.3 Preparation of negative solution
[0198] 2.3.1. Preparation of negative sample solution lacking Rehmannia glutinosa
[0199] Weigh other medicinal ingredients of Radix Rehmanniae according to the prescription, prepare a negative sample lacking Radix Rehmanniae according to the test sample preparation method, and prepare a negative sample solution lacking Radix Rehmanniae according to “2.2, Preparation of test sample solution”.
[0200] 2.3.2 Preparation of negative sample solution lacking yam
[0201] Weigh other medicinal ingredients of yam according to the prescription, prepare a negative sample without yam according to the test sample preparation method, and prepare a negative sample solution without yam according to "2.2, Preparation of test sample solution".
[0202] 2.3.3 Preparation of negative sample solution lacking wolfberry
[0203] Weigh other medicinal ingredients of wolfberry according to the prescription, prepare a negative sample lacking wolfberry according to the test sample preparation method, and prepare a negative sample solution lacking wolfberry according to "2.2, Preparation of test sample solution".
[0204] 2.3.4 Preparation of negative sample solution lacking licorice root
[0205] Weigh the other medicinal ingredients of Radix Glycyrrhizae Radix according to the prescription, prepare the negative sample without Radix Glycyrrhizae Radix according to the test sample preparation method, and prepare the negative sample solution without Radix Glycyrrhizae Radix according to "2.2, Preparation of test sample solution".
[0206] 2.3.5. Preparation of negative sample solution lacking Poria cocos
[0207] Weigh the other medicinal ingredients of Poria cocos according to the prescription, prepare a negative sample lacking Poria cocos according to the test sample preparation method, and prepare a negative sample solution lacking Poria cocos according to "2.2, Preparation of test sample solution".
[0208] 2.3.6 Preparation of negative sample solution lacking Cornus officinalis
[0209] Weigh the other medicinal ingredients of Cornus officinalis according to the prescription, prepare a negative sample lacking Cornus officinalis according to the test sample preparation method, and prepare a negative sample solution lacking Cornus officinalis according to "2.2, Preparation of test sample solution"
[0210] 2.4. Preparation of single negative solution
[0211] 2.4.1. Preparation of single negative sample solution of Radix Rehmanniae Preparata
[0212] Weigh Rehmannia glutinosa according to the prescription, prepare a negative sample of Rehmannia glutinosa according to the test sample preparation method, and prepare a negative sample solution of Rehmannia glutinosa according to “2.2, Preparation of test sample solution”.
[0213] 2.4.2 Preparation of single negative sample solution of yam
[0214] Weigh yam according to the prescription, prepare the negative sample of yam according to the test sample preparation method, and prepare the negative sample solution of yam according to "2.2, Preparation of test sample solution".
[0215] 2.4.3 Preparation of single negative sample solution of wolfberry
[0216] Weigh wolfberry according to the prescription, prepare the negative sample of wolfberry according to the test sample preparation method, and prepare the negative sample solution of wolfberry according to "2.2, Preparation of test sample solution".
[0217] 2.4.4 Preparation of single negative sample solution of Radix Glycyrrhizae Radix
[0218] Weigh roasted licorice root according to the prescription, prepare the negative sample of roasted licorice root according to the test sample preparation method, and prepare the negative sample solution of roasted licorice root according to "2.2, Preparation of test sample solution".
[0219] 2.4.5. Preparation of single negative sample solution of Poria cocos
[0220] Weigh Poria cocos according to the prescription, prepare the negative sample of Poria cocos according to the test sample preparation method, and prepare the negative sample solution of Poria cocos according to "2.2, Preparation of test sample solution".
[0221] 2.4.6 Preparation of single negative sample solution of Cornus officinalis
[0222] Weigh Fructus Corni according to the prescription, prepare the negative sample of Fructus Corni according to the test sample preparation method, and prepare the negative sample solution of Fructus Corni according to “2.2, Preparation of test sample solution”.
[0223] 3. Initial chromatographic conditions
[0224] Determined by high performance liquid chromatography (General Rules 0512 of Part IV of the 2020 edition of the Chinese Pharmacopoeia).
[0225] The chromatographic conditions and system suitability test used octadecylsilane bonded silica gel as filler; acetonitrile as mobile phase A, 0.1% phosphoric acid as mobile phase B; gradient elution was performed according to the provisions in Table 1; the detection wavelength was 190-400 nm. The theoretical plate number calculated based on the morroniside peak should be no less than 6000.
[0226] Table 1 Initial mobile phase gradient
[0227] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0~60 5→85 95→15 60~70 85→95 15→5 70~71 95→5 5→95 71~80 5 95
[0228] According to the separation of components in the compound, the gradient conditions are optimized and ultimately a better detection method is obtained.
[0229] 3.1. Mobile phase gradient selection
[0230] In order to make each main chromatographic peak in the chromatogram have better separation parameters and present better chromatographic behavior, the test solution in "2.2, Preparation of test solution" was taken to optimize the elution gradient. The optimized gradient program is as follows.
[0231] Table 2 Mobile phase gradient 1
[0232]
[0233]
[0234] Table 3 Mobile phase gradient 2
[0235] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0~15 5→6 95→94 15~40 6→20 94→80 40~50 20→30 80→70 50~58 30→54 70→46 58~65 54→60 46→40 65~70 60→70 40→30 70~71 70→5 30→95 71~80 5 95
[0236] Table 4 Mobile phase gradient 3
[0237] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0~6 0 100 6~15 0→6 100→94 15~25 6→12 94→88 25~40 12→15 88→85 40~50 15→20 85→80 50~60 20→22 80→78 60~70 22→40 78→60 70~80 40→60 60→40 80~81 60→5 40→95 81~85 5 95
[0238] Table 5 Mobile phase gradient 4
[0239]
[0240]
[0241] Table 6 Mobile phase gradient 5
[0242] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0~15 3 97 15~25 3→8 97→92 25~40 8→12 92→88 40~50 12→22 88→78 50~62 22→28 78→72 62~72 28→50 72→50 72~80 50→55 50→45 80~90 55→70 45→30 90~91 70→3 30→97 100 3 97
[0243] Agilent 5TC-C18 (2) (4.6 × 250 mm, 5 μm) SN: 723803 chromatographic column was selected, the detection wavelength was 256 nm, and elution was performed under the above 5 gradient programs.
[0244] The results showed that under gradient 1, the number of characteristic peaks was small and no characteristic peaks appeared within 25-55 minutes; under gradient 2, the characteristic peaks were not separated in the first 10 minutes, and the characteristic peaks did not meet the separation requirements within 55-60 minutes;
[0245] Under the gradient 3 condition, the characteristic peak did not meet the separation requirements within 15 to 22 minutes; under the gradient 5 condition, the characteristic peak did not meet the separation requirements around 35 minutes; under the gradient 4 elution program, the baseline was stable, the main chromatographic peaks were well separated, and the analysis time was within 80 minutes, so the gradient 4 chromatographic condition was temporarily selected for the characteristic spectrum determination.
[0246] Chromatographic conditions and system suitability test: octadecylsilane bonded silica gel is used as filler; acetonitrile is used as mobile phase A; 0.1% phosphoric acid solution is used as mobile phase B; gradient elution is performed according to the provisions in Table 5; the flow rate is 1.0 ml per minute; the column temperature is 30°C; the detection wavelength is 256 nm. The theoretical plate number should be no less than 5000 calculated based on the morroniside peak. Accurately aspirate 10 μl of the reference solution and the test solution respectively, inject them into the liquid chromatograph, and determine them.
[0247] 3.2 Validation of analytical methods
[0248] The fingerprint spectrum established above was systematically methodologically validated in accordance with the 9101 Analytical Method Validation Guidelines of Part IV of the 2020 Edition of the Chinese Pharmacopoeia and the National Drug Standard Work Manual (Fourth Edition).
[0249] 3.2.1. Exclusivity
[0250] Prepare negative blank sample solution according to the test solution preparation method, test it according to the above fingerprint method, and record the chromatogram.
[0251] The results showed that the 15 fingerprint peaks were assigned as shown in Table 7, with no interference in the negative test and good method specificity.
[0252] Table 7 Characteristic peak attribution table
[0253] name Compound Rehmannia root Yam Wolfberry Roasted Licorice Poria Dogwood Attributed to medicinal taste Peak 1 / + - + - - - Rehmannia root, wolfberry Peak 2 / + - - - - - Rehmannia root Peak 3 / + - - - - - Rehmannia root Peak 4 / - - - + - + Licorice root, Cornus officinalis Peak 5 Morroniside - - - - - + Dogwood Peak 6 / - - + - - - Wolfberry Peak 7 Loganin - - - - - + Dogwood Peak 8 Licorice glycoside - - - + - - Roasted Licorice Peak 9 / - - - - - + Dogwood Peak 10 / - - - - - + Dogwood Peak 11 / - - - + - - Roasted Licorice Peak 12 / - - - + - + Licorice root, Cornus officinalis Peak 13 / - - - + - - Roasted Licorice Peak 14 / - - - + - - Roasted Licorice Peak 15 Ammonium glycyrrhizinate - - - + - - Roasted Licorice
[0254] The results showed that the 15 fingerprint peaks were assigned as shown in Table 7. There was no negative interference and the method had good specificity. Peak 1 came from Rehmannia root and Lycium barbarum, peak 2 and peak 3 came from Rehmannia root, peak 4 and peak 12 came from Radix Glycyrrhizae Preparata and Fructus Corni, peak 5, peak 7, peak 9 and peak 10 came from Fructus Corni, peak 6 came from Fructus Lycium barbarum, peak 8, peak 11, peak 8 and peak 13 to peak 15 came from Radix Glycyrrhizae Preparata.
[0255] 3.3.2 Precision
[0256] 3.3.2.1. Instrument precision test
[0257] The same test solution was sampled 6 times continuously, the chromatogram was recorded, and the RSD of the relative retention time and relative peak area of each fingerprint peak was calculated.
[0258] The results showed that the relative retention time RSD of each common peak was 0.00% to 0.37%, less than 3%; the relative peak area RSD was 0.00 to 8.49%, among which the relative peak area RSD of peak 14 was 8.49%, which was related to the small peak area of the peak and was greatly affected by baseline fluctuations and instrument performance stability. The similarity of the instrument precision of this method was greater than 0.90, indicating that the instrument precision of this method was good.
[0259] 3.3.2.2 Intermediate precision (different operators)
[0260] Take the same batch of samples and have experimenters A, B, and C operate independently to prepare a test sample according to the test sample preparation method, record the chromatogram, and calculate the relative retention time and RSD of the relative peak area of each fingerprint peak.
[0261] The results showed that the relative retention time RSD of each common peak was 0.00-1.64%, less than 3%; the relative peak area RSD was 0.00-85.11%, of which the relative peak area RSD of peak 4 was 85.11%, which was related to the small peak area of this peak and was greatly affected by baseline fluctuations, instrument performance stability, etc. The similarity results of different operators were all greater than 0.90, which met the requirements.
[0262] 3.3.2.3 Intermediate precision (different experimental instruments)
[0263] Take the same test solution and test it on Agilent HPLC and Waters HPLC respectively according to the conditions determined above, record the chromatograms, and calculate the RSD of the relative retention time and relative peak area of each fingerprint peak.
[0264] The results show that the relative retention time RSD of each common peak is 0.00-1.28%; the relative peak area RSD is 0.00-24.64%. The relative peak area RSD deviation of peak 3 is large, which is related to the small peak area of this peak and is greatly affected by baseline fluctuations, instrument performance stability, different instrument parameters, etc. The similarity results of different instruments are greater than 0.90, which meets the regulations, indicating that different instruments have good separation effects for this method.
[0265] 3.3.2.4 Method repeatability test
[0266] Take 6 portions of the same batch of samples, 0.3 g each, accurately weigh them, prepare the test samples according to the method of "Preparation of Test Sample Solution", record the chromatogram, and calculate the relative retention time and relative peak area RSD of each fingerprint peak.
[0267] The results showed that the relative retention time RSD of each common peak was 0.00-0.29%; the relative peak area RSD was 0.00-22.39%. The similarity results of the repeatability were all greater than 0.90, which met the requirements.
[0268] 3.3.2.5 Durability
[0269] 3.3.2.5.1. Stability test
[0270] Take the same test solution and inject it at 0, 2h, 4h, 6h, 8h, 10h, 12h, 18h, 24h, 36h, 48h and 60h. Record the chromatogram, calculate the relative retention time and RSD of the relative peak area of each fingerprint peak, and examine the stability of the test solution.
[0271] The results showed that the stability was within 0-60 hours, the relative retention time RSD of each common peak was 0.00-0.82%, less than 3%, and the relative peak area RSD was 0.00-25.93%. The similarity result was greater than 0.90, which met the requirements, indicating that it was stable within 60 hours.
[0272] 3.3.2.5.2. Investigation of different flow rates
[0273] Take the same test solution and conduct tests at different flow rates of 0.8ml / min, 1.0ml / min and 1.2ml / min, record the chromatograms, and calculate the RSD of the relative retention time and relative peak area of each fingerprint peak.
[0274] The results showed that the relative retention time RSD of the common peaks was 0.00-10.7%; the relative peak area RSD was 0.00-97.11%, with a large deviation; the similarity results of different flow rates were all greater than 0.90, but in order to ensure the reproducibility of the method, a fixed flow rate of 1.0 ml / min was recommended.
[0275] 3.3.2.5.3. Investigation of different column temperatures
[0276] Take the same test solution and conduct tests at 30℃, 35℃ and 40℃ respectively, record the chromatograms, and calculate the RSD of the relative retention time and relative peak area of each fingerprint peak.
[0277] The results showed that the relative retention time RSD of the common peaks was 0.00-4.65%; the relative peak area RSD was 0.00-25.2%, with a large deviation; the similarity results of different column temperatures were all greater than 0.90, but in order to ensure the reproducibility of the method, it is recommended to fix the column temperature at 30°C.
[0278] 3.3.2.5.4. Investigation of mobile phases with different concentrations
[0279] The same test solution was taken and tested at the concentrations of 0.08%, 0.10% and 0.12% of phosphoric acid solution in the mobile phase. The chromatograms were recorded, and the RSD of the relative retention time and relative peak area of each fingerprint peak was calculated. The results showed that the RSD of the relative retention time of each common peak was 0.00-2.49%, less than 3%, and the similarity results of different acid concentrations were greater than 0.90, which was in line with the regulations.
[0280] 3.3.2.5.5 Different chromatographic columns
[0281] The same test solution was tested on different chromatographic columns (chromatographic column 1: Agilent 5TC-C18 (2) (4.6 × 250 mm, 5 μm) SN: 723746), (chromatographic column 2: Agilent 5TC-C18 (2) (4.6 × 250 mm, 5 μm) SN: 723803), (chromatographic column 3: Agilent 5TC-C18 (2) (4.6 × 250 mm, 5 μm) SN: 730900), and the chromatograms were recorded. The relative retention time and relative peak area RSD of each fingerprint peak were calculated, and the results are as follows. The standard decoction of Ge Jie Ji Tang was used for similarity matching calculation, and the results are as follows.
[0282] The results showed that the relative retention time RSD of the common peaks was 0.00-1.19%; the relative peak area RSD was 0.00-13.42%, with a small deviation; the similarity results of different chromatographic columns were all greater than 0.90, but in order to ensure the reproducibility of the method, it is recommended that the fixed chromatographic column be Agilent 5TC-C18(2)(250×4.6mm)SN:723803.
[0283] According to the results of the above methodological investigation, among the 15 common peaks of the established characteristic spectrum, each chromatographic peak is less affected by factors such as different brands of HPLC, different chromatographic columns, different column temperatures and flow rates, and the influence of other chromatographic conditions does not change much, indicating that the method has good durability, is stable and reliable, and can be used for characteristic spectrum determination.
[0284] The reference fingerprint of the test solution of the Chinese medicine compound decoction in this application is as follows Figure 1 shown.
[0285] 4. Characteristics of the standard
[0286] A total of 15 batches of benchmark samples were tested according to the above method, and the characteristic spectrum standard was finally determined based on the test results. Figure 2 shown.
[0287] 15 batches of reference samples with fixed extraction methods were used to establish templates according to the Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (Version 2.0) provided by the National Pharmacopoeia Committee to form a reference characteristic spectrum of Morus alba bark. The internal control quality specification value of the characteristic spectrum was formulated based on the average value of the relative retention time of each characteristic peak and the S peak. The judgment standard was: the characteristic peak presented in the chromatogram of the test sample should correspond to the retention time of the characteristic peak presented in the chromatogram of the reference medicinal material, and the peak corresponding to the morroniside reference peak was taken as the S peak. The relative retention time of each characteristic peak and the S peak was calculated, and the relative retention time should be within the range of ±10% of the specified value.
[0288] Based on the above results, the fingerprint method of this application is determined as follows:
[0289] Chromatographic conditions and system suitability: octadecylsilane bonded silica gel as filler; acetonitrile as mobile phase A; 0.1% phosphoric acid solution as mobile phase B; gradient elution as specified in Table 5; flow rate 1.0 ml per minute; column temperature 30°C; detection wavelength 256 nm. The theoretical plate number calculated based on the morroniside peak should be no less than 5000.
[0290] Preparation of reference solution: Accurately weigh ammonium glycyrrhizinate, liquiritin, morroniside, and loganin, add methanol to dissolve, and prepare mixed reference solutions of 0.07915 mg / ml, 0.07868 mg / ml, 0.08645 mg / ml, and 0.08316 mg / ml, respectively.
[0291] Preparation of test solution: Take 6.5g of Rehmannia glutinosa (steamed), 6.0g of Chinese yam, 6.0g of Chinese wolfberry, 3.0g of roasted licorice root, 4.5g of Poria cocos, and 4.0g of Cornus officinalis, add 10 times the amount of water, and soak for 30 minutes. Boil over high heat and continue to decoct for 50 minutes, and filter out the liquid. Decoction for the second time, add 8 times the amount of water, decoct over high heat until boiling, then simmer over low heat for 40 minutes, and filter out the liquid. Combine the filtrates from the two decoctions to obtain the solution.
[0292] Preparation of test solution: Accurately measure 5 ml of the reference substance and place it in a 10 ml volumetric flask, add methanol to dilute to the scale, shake well, filter, and take the filtrate to obtain the solution.
[0293] Determination method: Accurately aspirate 10 μl of reference solution and test solution respectively, inject into liquid chromatograph, and determine.
[0294] The embodiments of the present invention are described in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core idea. At the same time, changes or deformations made by those skilled in the art based on the ideas of the present invention, the specific implementation methods and application scope of the present invention, all belong to the scope of protection of the present invention. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. A method for constructing a fingerprint of a traditional Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum, characterized in that: The construction method comprises the following steps: Preparation of the test solution: taking an appropriate amount of the Chinese medicine composition solution and adding it into a container, adding methanol to dilute, shaking, filtering, and taking the filtrate to obtain the Chinese medicine composition test solution; wherein the Chinese medicine composition is composed of Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis; Preparation of reference solution: weigh appropriate amounts of ammonium glycyrrhizinate, liquiritin, morroniside and loganin reference substances, add methanol to prepare the reference solution with concentrations of ammonium glycyrrhizinate, liquiritin, morroniside and loganin of 5 to 400 μg / ml respectively; Obtaining a fingerprint of the Chinese medicine composition according to the results of high performance liquid chromatography detection of the test solution and the reference solution; The chromatographic conditions for HPLC detection are as follows: using an Agilent 5TC-C18(2)SN:723803 chromatographic column, the mobile phase A is acetonitrile, the mobile phase B is about 0.1% phosphoric acid aqueous solution, the gradient elution program is: 0-15 min, 5% A; 15-25 min, 5%→8% A; 25-40 min, 8%→12% A; 40-50 min, 12%→22% A; 50-65 min, 22%→30% A; 65-80 min, 30%→60% A; 80-90 min, 60%→70% A; 90-91 min, 70%→5% A; 91-100 min, 5% A; the flow rate is 0.5-1.5 mL / min, the column temperature is 20-40°C, the detection wavelength is 256 nm, and the injection volume is 5-15 μl; Wherein, when the detection wavelength is 256nm, the fingerprint spectrum includes peaks 1-15, wherein peak 1 belongs to the medicinal flavor of Rehmannia root and Lycium barbarum; peaks 2 and 3 belong to the medicinal flavor of Rehmannia root; peaks 4 and 12 belong to the medicinal flavors of Licorice and Cornus officinalis; peaks 5, 7, 9 and 10 belong to the medicinal flavor of Cornus officinalis; peak 6 belongs to the medicinal flavor of Lycium barbarum; peaks 8, 11, 13, 14 and 15 belong to the medicinal flavor of Licorice, peak 5 is the chromatographic peak of Morroniside, peak 7 is the chromatographic peak of Loganin, peak 8 is the chromatographic peak of Liquorice glycoside, and peak 15 is the chromatographic peak of Ammonium Glycyrrhizinate; The fingerprint spectrum includes 15 characteristic chromatographic peaks at a detection wavelength of 256 nm, with the chromatographic peak of morroniside No. 5 as the reference peak, and the relative retention times of the other 14 characteristic chromatographic peaks are: peak 1 0.3228±10%, peak 2 0.3562±10%, peak 3 0.5173±10%, peak 4 0.9570±10%, peak 6 1.0948±10%. 0%, peak 7 1.3965±10%, peak 8 1.6413±10%, peak 9 1.6572±10%, peak 10 1.7666±10%, peak 11 1.9100±10%, peak 12 2.2074±10%, peak 13 2.2475±10%, peak 14 2.3098±10% and peak 15 2.3492±10%.
2. The construction method according to claim 1, characterized in that: The container is a measuring bottle.
3. The construction method according to claim 1, characterized in that: The volume / volume ratio between the Chinese medicine composition solution and the methanol is 0.5-5, ml / ml.
4. The construction method according to claim 3, characterized in that: The volume / volume ratio between the Chinese medicine composition solution and the methanol is about 1, ml / ml.
5. The construction method according to claim 1, characterized in that: The volume of the Chinese medicine composition solution is 1 to 10 ml.
6. The construction method according to claim 5, characterized in that: The volume of the Chinese medicine composition solution is about 5 ml.
7. The construction method according to claim 1, characterized in that: The flow rate is 0.8-1.2 ml / min.
8. The construction method according to claim 7, characterized in that: The flow rate was about 1.0 mL / min.
9. The construction method according to claim 1, characterized in that: The column temperature is 25-35°C.
10. The construction method according to claim 9, characterized in that: The column temperature was about 30°C.
11. The construction method according to claim 1, characterized in that: The injection volume is 8 to 12 μl.
12. The construction method according to claim 11, characterized in that: The injection volume was about 10 μl.
13. The construction method according to claim 1, characterized in that: The reference substance solution is a mixed solution of about 79.15 μg / ml of ammonium glycyrrhizinate, about 78.68 μg / ml of liquiritin, about 86.45 μg / ml of morroniside, and about 83.16 μg / ml of loganin.
14. The construction method according to claim 1, characterized in that: The theoretical plate number of the chromatographic peak corresponding to the morroniside is greater than 5000.
15. The construction method according to claim 1, characterized in that: The separation degree of the chromatographic peaks corresponding to the reference substance is greater than 1.
5.
16. The construction method according to claim 1, characterized in that: The specifications of the chromatographic column are: column length 250 mm, inner diameter 4.6 mm, and particle size 5 μm.
17. The construction method according to claim 1, characterized in that: The preparation method of the Chinese medicine composition solution comprises: (a) weighing an appropriate amount of the Chinese medicine composition, adding a first water for soaking, decocting for a first time until boiling over high heat, then continuing to decoct for a period of time, filtering, and obtaining a medicine residue and a first medicine decoction, (b) adding a second water to the medicine residue, decocting for a second time until boiling over high heat, then changing to a slow heat for decoction, filtering, and obtaining a second medicine decoction, and (c) combining the first medicine decoction and the second medicine decoction to obtain the Chinese medicine composition solution.
18. The construction method according to claim 17, characterized in that: The water is purified water or distilled water.
19. The construction method according to claim 17, characterized in that: The mass / volume ratio between the traditional Chinese medicine composition and the first water is 0.05-1.
20. The construction method according to claim 19, characterized in that: The mass / volume ratio between the traditional Chinese medicine composition and the first water is about 0.
1.
21. The construction method according to claim 17, characterized in that: The mass / volume ratio between the traditional Chinese medicine composition and the second water is 0.05-1.
22. The construction method according to claim 21, characterized in that: The mass / volume ratio between the traditional Chinese medicine composition and the second water is about 0.
125.
23. The construction method according to claim 17, characterized in that: The first water soaking time is 10 to 60 minutes.
24. The construction method according to claim 23, characterized in that: The first water soaking time is about 30 minutes.
25. The construction method according to claim 17, characterized in that: The continuing to boil for a period of time is continuing to boil for 10 to 90 minutes.
26. The construction method according to claim 25, characterized in that: The continued decocting for a period of time is continued decocting for about 50 minutes.
27. The construction method according to claim 17, characterized in that: The slow fire decocting time is 10 to 90 minutes.
28. The construction method according to claim 27, characterized in that: The slow-cooking time is about 40 minutes.
29. The construction method according to claim 17, characterized in that: In the traditional Chinese medicine composition, the mass ratio of Rehmannia root, Chinese yam, Chinese wolfberry, liquorice, Poria cocos and Cornus officinalis is (1-10):(1-10):(1-10):(1-10):(1-10):(1-10).
30. The construction method according to claim 29, characterized in that: In the traditional Chinese medicine composition, the mass ratios of rehmannia root, yam, wolfberry, liquorice, tuckahoe and cornus officinalis are about 6.5: about 6.0: about 6.0: about 3.0: about 4.5: about 4.
0.
31. The construction method according to claim 1, characterized in that: The Rehmannia root is Rehmannia root prepared.
32. The construction method according to claim 1, characterized in that: The licorice is roasted licorice.
33. The construction method according to claim 1, characterized in that: When the detection wavelength is 256nm, the retention times of peaks 1-15 are 10.598±10%, 11.697±10%, 16.986±10%, 31.422±10%, 32.835±10%, 35.948±10%, 45.854±10%, 53.890±10%, 54.412±10%, 58.003±10%, 62.713±10%, 72.479±10%, 73.793±10%, 75.839±10% and 77.132±10%, respectively.
34. A quality control method for a Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum, characterized in that: The quality control method comprises the following steps: (1) Establishing a standard fingerprint of a reference sample of a Chinese medicine composition according to the fingerprint construction method described in any one of claims 1 to 33; (2) taking a sample solution of the Chinese medicine composition, and testing it according to the chromatographic conditions in the fingerprint construction method according to any one of claims 1 to 33 to obtain a fingerprint of the Chinese medicine composition sample to be tested; as well as (3) Compare the fingerprint of the Chinese medicine composition sample obtained in step (2) with the standard fingerprint of the Chinese medicine composition reference sample obtained in step (1). If it meets the requirements, it is a qualified product, and if it does not meet the requirements, it is an unqualified product.
35. The quality control method according to claim 34, characterized in that: The compliance requirements include one or more of the following: (1) The fingerprint of the Chinese medicine composition sample to be tested presents 15 characteristic chromatographic peaks, and the retention time of each characteristic chromatographic peak is within ±10% of the retention time value of the corresponding reference chromatographic peak in the standard fingerprint of the Chinese medicine composition reference sample; (2) With the chromatographic peak of morroniside as peak S, the relative retention time between each characteristic chromatographic peak in the fingerprint of the Chinese medicine composition sample to be tested and peak S is within ±10% of the relative retention time value of each characteristic chromatographic peak in the standard fingerprint of the Chinese medicine composition reference sample; as well as (3) According to the similarity evaluation system of Chinese medicine chromatographic fingerprint, the similarity between the fingerprint of the Chinese medicine composition sample to be tested and the standard fingerprint of the Chinese medicine composition reference sample is calculated, and the similarity shall not be less than 0.
90.
36. Use of the construction method according to any one of claims 1 to 33 or the quality control method according to claim 34 or 35 in quality detection, quality evaluation or quality control of a traditional Chinese medicine composition comprising Rehmannia root, Cornus officinalis and Lycium barbarum.
